专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20100267816A1 HUMAN ANTI-AMYLOID BETA PEPTIDE ANTIBODY AND FRAGMENT OF SAID ANTIBODY 有权
标题翻译：人抗甲状腺肽抗体和抗体抗体片段
公开(公告)号：US20100267816A1
公开(公告)日：2010-10-21
申请号：US12792064
申请日：2010-06-02
申请人： Kazuhisa SUGIMURA , Toshihiro Nakashima
发明人： Kazuhisa SUGIMURA , Toshihiro Nakashima
IPC分类号： A61K31/711 , C12P21/04 , C12N1/21 , C12N15/63 , C07H21/04 , A61P25/28
CPC分类号： G01N33/6896 , A61K31/7088 , A61K48/00 , C07K16/18 , C07K2317/21 , C07K2317/622 , G01N2333/4709 , G01N2800/2821
摘要： A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody, strongly reacts with Aβ to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.
摘要翻译：人类抗淀粉样蛋白与A＆bgr结合的肽（以下称为“A＆bgr”）抗体; 从而抑制A＆bgr的聚集; 分子和所述抗体的片段。根据本发明的抗体及其片段，其包含人衍生的抗A＆Bgr的可变区; 抗体与A＆bgr强烈反应; 从而抑制其聚集，因此可以用作预防和治疗阿尔茨海默氏痴呆的药物。

32. 发明授权

US07807161B2 Humanized anti-human osteopontin antibody 失效
标题翻译：人源化抗人骨桥蛋白抗体
公开(公告)号：US07807161B2
公开(公告)日：2010-10-05
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
IPC分类号： A61K39/00 , A61K39/395 , C07K16/46 , C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译：本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体抗人骨桥蛋白抗体。

33. 外观设计

USD619581S1 Electronic pen 有权
公开(公告)号：USD619581S1
公开(公告)日：2010-07-13
申请号：US29356746
申请日：2010-03-02
申请人： Atsushi Tani , Toshihiro Nakashima
设计人： Atsushi Tani , Toshihiro Nakashima

34. 发明授权

US07491803B2 Human anti-human interleukin-18 antibody, fragment thereof and method for using same 失效
标题翻译：人抗人白介素-18抗体及其片段及其使用方法
公开(公告)号：US07491803B2
公开(公告)日：2009-02-17
申请号：US10555074
申请日：2004-04-30
申请人： Kazuhisa Sugimura , Kenji Nakanishi , Toshihiro Nakashima
发明人： Kazuhisa Sugimura , Kenji Nakanishi , Toshihiro Nakashima
IPC分类号： C07K16/00 , C12N15/09
CPC分类号： C07K16/244 , C07K2317/21 , C07K2317/565
摘要： A human-derived human anti-human IL-18 antibody of the present invention is an antibody against human IL-18, the antibody including: an H-chain complementarity determining region consisting of (a) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4 to 6, or (b) a polypeptide which is a mutant of the polypeptide (a) and which serves as the H-chain complementarity determining region; and an L-chain complementarity determining region against human interleukin-18 consisting of (c) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 10 to 12, or (d) a polypeptide which is a mutant of the polypeptide (c) and which serves as the L-chain complementarity determining region. This makes it possible to provide a human anti-human IL-18 antibody and a method for using the antibody.
摘要翻译：本发明的人衍生的人抗人IL-18抗体是针对人IL-18的抗体，所述抗体包括：H链互补决定区，其由（a）由氨基酸序列表示的多肽组成通过SEQ ID NO：4至6，或（b）多肽（a）的突变体并用作H链互补决定区的多肽; 和由（c）由SEQ ID NO：10至12表示的氨基酸序列组成的多肽的人白介素-18组成的L链互补决定区，或（d）多肽突变体的多肽（ c）并且其用作L链互补决定区。这使得可以提供人抗人IL-18抗体和使用该抗体的方法。

35. 发明申请

US20080138860A1 Method For Improving Antibody 有权
标题翻译：改善抗体的方法
公开(公告)号：US20080138860A1
公开(公告)日：2008-06-12
申请号：US11815838
申请日：2006-02-07
申请人： Masaharu Torikai , Toshihiro Nakashima
发明人： Masaharu Torikai , Toshihiro Nakashima
IPC分类号： C12P21/00 , C07K16/00
CPC分类号： C07K16/00 , C07K16/1271 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/567 , C07K2317/94
摘要： The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.
摘要翻译：本发明提供了改善抗体性质的方法，例如表达水平和稳定性。通过修饰人抗体或人源化抗体获得具有改善的表达水平和/或稳定性的抗体的方法，其特征在于，第8,12,15或18位的氨基酸残基中的至少任一种（根据Kabat 编号）在人抗体或人源化抗体的轻链可变区（以下称为“VL链”）中被除脯氨酸或半胱氨酸以外的不同氨基酸，人抗体或人源化抗体或人抗体片段或具有通过所述方法获得的改善的表达水平和/或稳定性的人源化抗体片段。

36. 发明授权

US07214785B2 Human-type anti-blood coagulation factor VIII antibody 失效
标题翻译：人类抗凝血因子VIII抗体
公开(公告)号：US07214785B2
公开(公告)日：2007-05-08
申请号：US10344514
申请日：2002-06-11
申请人： Toshihiro Nakashima , Masato Yuguchi
发明人： Toshihiro Nakashima , Masato Yuguchi
IPC分类号： C07H21/04
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K14/755 , C07K16/36 , C07K2317/21 , C07K2317/622 , G01N33/86
摘要： The present invention provides a human antibody against blood coagulation factor VIII (hereinafter also referred to as “FVIII”) and an antibody fragment that binds to human FVIII and specifically inhibits the coagulation activity of human FVIII. ScFv display phage libraries, prepared by using scFv DNAs constructed by random combinations of immunoglobulin VH chain genes and VL chain genes from lymphocytes from hemophilia A patients, is reacted with FVIII immobilized to a solid phase via anti-FVIII monoclonal antibody, and scFv clones capable of binding to FVIII are cloned to reveal VH and VL chains of FVIII-specific antibody.
摘要翻译：本发明提供了针对凝血因子VIII（以下也称为“FVIII”）的人抗体和与人FVIII结合并特异性抑制人FVIII凝血活性的抗体片段。通过使用通过免疫球蛋白VH链基因的随机组合构建的scFv DNA和来自血友病A患者的淋巴细胞的VL链基因制备的ScFv显示噬菌体文库通过抗FVIII单克隆抗体与能够固定在固相上的FVIII反应，以及具有能力的scFv克隆克隆与FVIII结合以揭示FVIII特异性抗体的VH和VL链。

37. 发明授权

US08226958B2 Modified SEB and prophylactics/remedies for immunopathy containing the same 失效
标题翻译：修饰的SEB和预防药物/含有其的免疫疾病的补救措施
公开(公告)号：US08226958B2
公开(公告)日：2012-07-24
申请号：US10551263
申请日：2004-03-25
申请人： Toshihiro Nakashima , Takumi Sasaki , Kazuhiko Kimachi , Shigeki Kuwata , Tsukasa Nishihara , Atsuko Sakata , Masao Ohkuchi , Tomoyuki Koshi , Toshiyuki Edano
发明人： Toshihiro Nakashima , Takumi Sasaki , Kazuhiko Kimachi , Shigeki Kuwata , Tsukasa Nishihara , Atsuko Sakata , Masao Ohkuchi , Tomoyuki Koshi , Toshiyuki Edano
IPC分类号： A61K39/00 , A61K39/02 , A61K39/085 , C07K1/00 , C07K14/00 , C07K17/00
CPC分类号： A61K38/164 , C07K14/31 , C07K16/1271
摘要： A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.
摘要翻译：提供一种免疫病的新型预防/治疗方法，其不被被称为超抗原之一的葡萄球菌肠毒素B（SEB）的中和抗体中和，并且可以有效地作为超抗原。与SEB中和抗体（抗SEB抗体）具有降低的反应性的修饰SEB和用于免疫病的预防/治疗方法，其包含所述经修饰的SEB作为活性成分。本发明的经修饰的SEB可以通过在SEB的氨基酸序列中引入氨基酸取代，特别是在SEB的氨基酸序列中的抗SEB抗体的表位识别位点处进行进化分子工程技术来制备。

38. 外观设计

USD635561S1 Private branch exchange 有权
标题翻译：私人交流
公开(公告)号：USD635561S1
公开(公告)日：2011-04-05
申请号：US29304395
申请日：2008-02-29
申请人： Toshihiro Nakashima
设计人： Toshihiro Nakashima

39. 发明申请

US20110014213A1 HUMAN ANTI-ALPHA 9 INTEGRIN ANTIBODY 有权
标题翻译：人类抗ALPHA 9整合抗体
公开(公告)号：US20110014213A1
公开(公告)日：2011-01-20
申请号：US12810939
申请日：2008-12-26
申请人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
发明人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/02 , A61P19/02
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/622 , C07K2317/92 , C07K2319/00
摘要： The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-α9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.
摘要翻译：本发明提供一种人抗α9整联蛋白抗体或特异性识别人α9整联蛋白和小鼠α9整联蛋白的抗体片段，抑制与其配体的相互作用，特别是识别人和小鼠α9整联蛋白环区的抗体或抗体片段，编码抗体或抗体片段的基因，含有该基因的重组表达载体，携带该基因的转化体，使用该转化体的人抗α9整联蛋白抗体的制备方法或抗体片段，以及预防或治疗类风湿性关节炎其含有抗体或抗体片段。

40. 发明授权

US07763249B2 Human anti-amyloid β peptide antibody and fragment of said antibody 失效
标题翻译：人抗淀粉样蛋白肽抗体和所述抗体的片段
公开(公告)号：US07763249B2
公开(公告)日：2010-07-27
申请号：US11579072
申请日：2005-04-21
申请人： Kazuhisa Sugimura , Toshihiro Nakashima
发明人： Kazuhisa Sugimura , Toshihiro Nakashima
IPC分类号： A61K39/395 , C07K16/18 , C12P21/08
CPC分类号： G01N33/6896 , A61K31/7088 , A61K48/00 , C07K16/18 , C07K2317/21 , C07K2317/622 , G01N2333/4709 , G01N2800/2821
摘要： A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody, strongly reacts with Aβ to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.
摘要翻译：人类抗淀粉样蛋白与A＆bgr结合的肽（以下称为“A＆bgr”）抗体; 从而抑制A＆bgr的聚集; 分子和所述抗体的片段。根据本发明的抗体及其片段，其包含人衍生的抗A＆Bgr的可变区; 抗体与A＆bgr强烈反应; 从而抑制其聚集，因此可以用作预防和治疗阿尔茨海默氏痴呆的药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式